.png)
AKASA
We're Hiring!
AKASA Company Growth, Stability & Outlook
What People Are Saying About AKASA
-
Investor Backing & Capital Strength: A $120M Series C reported on June 18, 2024 provides substantial runway to scale a late‑stage health‑AI model. Industry trackers such as CB Insights and Becker’s cite this funding event, indicating fresh capital support.
-
Product Line Growth: Multiple launches in 2024–2025—Authorization Advisor, AKASA Medical Coding, and CDI Optimizer—signal an expanding roadmap and deeper coverage of mid‑cycle workflows. This cadence reflects ongoing investment to widen solution breadth.
-
Strategic Partnerships: A collaboration with Cleveland Clinic announced in April 2025 and deepened in October 2025 highlights enterprise‑scale deployment of AKASA’s GenAI tools. Coverage of real‑world outcomes (e.g., Nebraska Methodist’s reported gains) points to deployments beyond pilots.
